Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OSTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| LmddA-LLO-chHER2 Fusion Protein-secreting… | Bone Cancer | Phase 2 · NCT04974008 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OSTX holds $431,816 in cash and short-term investments (as of Sep 30, 2026) and burns about $5.1M/quarter from operations, an estimated runway of 0.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 84 · High
The Company’s current cash balance is insufficient to fund operations, which raises substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OSTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 5%+ holder (13G) | 5,434,150 | 10.39% | 2026-09-30 |
| Shalom Auerbach Former 10% Owner |
Insider | 2,677,570 | 5.12% | 2025-07-29 |
| Paul A. Romness President and CEO, Director · +3.40M options |
Insider | 2,473,000 | 4.73% | 2026-10-22 |
| Vanguard Capital Management LLC | Institution (13F) | 777,651 | 1.49% | 2026-09-30 |
| John Ciccio Director · +530,000 options |
Insider | 455,835 | 0.87% | 2026-10-22 |
| Theodore F. Search Director · +530,000 options Includes shares also reported by John Ciccio, counted once |
Insider | 455,835 | 0.87% | 2026-10-22 |
| Geode Capital Management, LLC | Institution (13F) | 370,948 | 0.71% | 2026-09-30 |
| Knuettel II Francis Chief Financial Officer · +1.05M options |
Insider | 270,000 | 0.52% | 2026-11-10 |
| Howard Financial Services, Ltd. | Institution (13F) | 248,001 | 0.47% | 2026-09-30 |
| Citadel Advisors Llc | Institution (13F) | 245,856 | 0.47% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 245,147 | 0.47% | 2026-09-30 |
| Colin Goddard Director · +400,000 options |
Insider | 225,179 | 0.43% | 2024-12-31 |
Share count 52,300,709 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-10 filed 2026-11-12 |
Francis Knuettel II |
Award (A) | 250,000 | – | 250,000 |
| 2026-11-10 filed 2026-11-12 |
Francis Knuettel II |
Option award (A) | 750,000 | – | – |
| 2026-11-10 filed 2026-11-12 |
Clem Kerry M |
Award (A) | 200,000 | – | 225,000 |
| 2026-11-10 filed 2026-11-12 |
Clem Kerry M |
Option award (A) | 700,000 | – | – |
| 2026-10-22 filed 2026-10-30 |
Francis Knuettel II |
Option award (A) | 300,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OSTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →